ASTMH 61st Annual Meeting

11-15 November 2012
Atlanta, Georgia, USA

MMV will be participating in the following sessions at ASTMH. Download the MMV programme. [PDF: 2.45Mb]

Symposium: session 15
Marriott, Marquis B, Monday, 12 Nov, 10:15 am – 12:00 pm
Drug discovery strategy for malaria eradication

Symposium organizer: Brice Campo, MMV, Switzerland
Co-chairperson: Philip Rosenthal, University of California, USA

Speakers
10:15 am New tools to discover liver-stage drugs for human malaria
Dennis E. Kyle, University of South Florida, USA

10:40 am Culturing of Plasmodium vivax to develop sporozoites
Kasturi Haldar, University of Notre Dame, USA

11:05 am Developing the next generation of high content / high throughput assays to identify novel antimalarials with transmission-blocking activity
Vicky M. Avery, Griffith University, Australia

11:30 am Assays to screen for transmission-blocking drugs
Michael Delves, Imperial College London, UK

 


 

Scientific session 30
Marriott, Marquis B, Monday, 12 Nov, 1:45 pm – 3:30 pm
Malaria drug development: primaquine and new developments

Co-Chairs Mark Baker, MMV, Switzerland
Prabhati Ray, Walter Reed Army Institute of Research, USA

Speakers
1:45 pm 431. ELQ-300 for treatment and prevention of malaria,
Michael K. Riscoe, Oregon Health & Science University, USA

2:00 pm 432. Potential efficacy of Citicoline as adjunct therapy for cerebral malaria
Ronan Jambou, Institut Pasteur de Madagascar, Madagascar

2:15 pm 433. Pathways to hemolytic toxicity of primaquine: Evaluation of potential hemotoxic metabolites of primaquine and aminophenol analogs in vitro on normal and glucose 6-phosphate dehydrogenase deficient human erythrocytes
Babu L. Tekwani, University of Mississippi, USA

2:30 pm 434. An in vivo glucose-6-phosphate dehydrogenase (G6PD)-deficient mouse model to predict hemolytic toxicity of candidate 8-aminoquinoline (8-AQ) antimalarial drugs
Prabhati Ray, Walter Reed Army Institute of Research, USA

2:45 pm 435. Phase I study to investigate the haemolytic potential of tafenoquine in healthy subjects with G6PD deficiency (TAF110027)
Ronnatrai Rueangweerayut, Mae Sot General Hospital, Thailand

3:00 pm 436. Using human blood stage P. falciparum infection to define the activity of licensed and experimental antimalarial drugs
James S. McCarthy, University of Queensland, Australia

3:15 pm 437. A population pharmacokinetic analysis of OZ439 disposition in patients
Mark B. Baker, MMV, Switzerland

 


 

Symposium: session 57
Marriott, Marquis D, Tuesday, 13 Nov 2012, 8:00 am – 9:45 am (Breakfast will be available)
Evaluating the modelling effects of implementing multiple first-line (MFL) artemisinin combination therapy (ACT) treatments versus real-life data

Symposium organizer: Ric Price, Menzies School of Health Research, Australia
Co-chairperson: Pierre Hugo, MMV, Switzerland

Speakers
8:00 am Modelling the impact of implementing different ACTs as first-line therapy
Azra Ghani, Imperial College London, UK

8:20 am Modelling the benefits of implementing MFL treatments in Ghana within high and low transmission settings: INDEPTH Effectiveness and Safety Study (INESS) sites for antimalarials
Fred Binka, University of Ghana, Ghana

8:40 am Modelling the benefits of implementing MFL treatments in Tanzania within high transmission and low transmission settings. How does the modelling data complement INESS results data?
Don de Savigny, Swiss TPH, Switzerland

9:05 am Modelling vs. real-life setting’s longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria
Grant Dorsey, University of California, USA

 


 

Symposium: session 144
Marriott, Marquis A, Wednesday, 14 Nov, 4:00 pm – 5:45 pm
Partnerships against malaria

Symposium organizer: Wilfred Fon Mbacham, The Multilateral Initiative on Malaria, Cameroon
Co-chairperson: Abdoulaye A. Djimde, University of Bamako, Mali

Speakers
10:15 am The Worldwide Antimalarial Resistance Network (WWARN)
Philippe Guérin, WWARN, UK

4:20 pm The production of semi-synthetic artermisinins
Nina Grove, One World Health, USA

4:40 pm Training of public health professionals and scientists, the Ifakara (Tanzania) and Madagascar experience
Milijoan Randrianariveljosia, Institut Pasteur, Madagascar

5:00 pm New antimalarials: addressing the risk of resistance development and planning for elimination
Stephan Duparc, MMV, Switzerland

 


 

Poster presentations

Hilton, Galleria Hall, Monday, 12 Nov 2012, 12:00 pm – 1:45 pm
Session 24: Poster Session A Presentations and Light Lunch

150. A randomized, placebo-controlled study to evaluate the effect of tafenoquine on the electrocardiogram (ECG), with focus on cardiac repolarization (QTc duration) in healthy subjects
Justin A. Green, Apurva K. Patel, Azra Hussaini, Emma J. Harrell, Mirna J. McDonald, Ann K. Miller, Stephan Duparc

Hilton, Galleria Hall, Wednesday, 14 Nov 2012, 12:00 pm – 1:45 pm
Session 128: Poster Session C Presentations and Light Lunch

1292. The drug-drug interaction potential of anti-malarial agents
Mark Baker

 


 

More information about this event is available on the ASTMH website.